Key statistics
On Friday, Roche Holding AG (ROG:SWX) closed at 341.20, -8.99% below its 52-week high of 374.90, set on Feb 24, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 345.00 |
|---|---|
| High | 346.50 |
| Low | 339.30 |
| Bid | 341.10 |
| Offer | 341.20 |
| Previous close | 351.50 |
| Average volume | 1.24m |
|---|---|
| Shares outstanding | 809.25m |
| Free float | 731.55m |
| P/E (TTM) | 22.37 |
| Market cap | 291.81bn CHF |
| EPS (TTM) | 16.04 CHF |
| Annual div (ADY) | 9.80 CHF |
|---|---|
| Annual div yield (ADY) | 2.79% |
| Div ex-date | Mar 27 2025 |
| Div pay-date | Mar 31 2025 |
| Next div ex-date | Mar 12 2026 |
| Next div pay-date | Mar 16 2026 |
Data delayed at least 15 minutes, as of Mar 06 2026 16:34 GMT.
More ▼
- New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
- [Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
- FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
- Change to the Roche Enlarged Corporate Executive Committee
- Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
- Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
- [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
More ▼
